-
公开(公告)号：US20170348310A1
公开(公告)日：2017-12-07
申请号：US15684733
申请日：2017-08-23
Applicant: Array BioPharma Inc. , Genentech, Inc.
Inventor： James F. Blake , Adam Cook , Indrani W. Gunawardana , Kevin W. Hunt , Michael Lyon , Andrew T. Metcalf , Peter J. Mohr , David A. Moreno , Brad Newhouse , Li Ren , Tony P. Tang , Allen A. Thomas , Jacob Schwarz , Jane Schmidt , Lewis Gazzard , Huifen Chen
IPC: A61K31/506 , C07D417/14 , C07D405/14 , C07D403/04 , A61K31/4439 , C07D401/14 , A61K45/06 , A61K31/444 , C07D471/04 , C07D403/14
CPC classification number: A61K31/506 , A61K31/4439 , A61K31/444 , A61K45/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D417/14 , C07D471/04
Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
-
12.发明申请公开(公告)号：US20170260168A1
公开(公告)日：2017-09-14
申请号：US15333148
申请日：2016-10-24
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , James F. Blake , Adam Cook , Indrani W. Gunawardana , Kevin W. Hunt , Andrew T. Metcalf , David Moreno , Li Ren , Tony P. Tang
IPC: C07D403/14 , A61K31/501 , G01N33/574 , A61K31/5377 , C07D401/14 , C12Q1/68 , A61K45/06 , C07D413/14
CPC classification number: C07D403/14 , A61K31/501 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D413/14 , C12Q1/6886 , G01N33/574
Abstract: Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.
-
公开(公告)号：US09670208B2
公开(公告)日：2017-06-06
申请号：US15197445
申请日：2016-06-29
Applicant: Array BioPharma Inc. , Genentech, Inc.
Inventor： James F. Blake , Adam Cook , John Gaudino , Indrani W. Gunawardana , Erik James Hicken , Kevin W. Hunt , Michael Lyon , Andrew T. Metcalf , Peter J. Mohr , David A. Moreno , Brad Newhouse , Li Ren , Jacob Schwarz , Huifen Chen , Lewis Gazzard , Jane Schmidt , Steve Do
IPC: C07D471/04 , A61K45/06 , A61K31/5377 , A61K31/506 , A61K31/444 , C07D487/04 , C07D519/00 , A61K31/55
CPC classification number: C07D471/04 , A61K31/444 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K45/06 , C07D487/04 , C07D519/00
Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such diseases, or associated pathological conditions are disclosed.
-
![CRYSTALLINE FORMS OF (1S)-1-[5-(AMINO)-1,2,4-THIADIAZOL-3-YL]ETHANE-1,2-DIOL](/abs-image/US/2015/10/22/US20150299182A1/abs.jpg.150x150.jpg)
14.发明申请CRYSTALLINE FORMS OF (1S)-1-[5-(AMINO)-1,2,4-THIADIAZOL-3-YL]ETHANE-1,2-DIOL 审中-公开（1S）-1- [5-（氨基）-1,2,4-三唑-3-基]乙基] -1,2-二醇的晶体形式公开(公告)号：US20150299182A1
公开(公告)日：2015-10-22
申请号：US14441133
申请日：2013-11-08
Applicant: Array BioPharma Inc. , Amgen Inc.
Inventor： Sylvie Asselin , Lisa Brett , Ying Chen , Donald T. Corson , Andrew Cosbie , Robert Farrell , Indrani W. Gunawardana , Jinkun Huang , Jonathan W. Lane , Dennis Lei , Christopher M. Lindemann , Van Luu , Coralee G. Mannila , Robert Milburn , Henry Morrison , Helming Tan , Jason Tedrow , Daniel J. Watson
IPC: C07D417/14
CPC classification number: C07D417/14 , C07B2200/13
Abstract: The present invention relates to crystalline polymorph forms of (1S)-1-[5-({3-[(2-methylpyridin-3-yl)oxy]-5-(pyridin-2-ylsulfanyl)pyridin-2-yl}amino)-1,2,4-thiadiazol-3-yl]ethane-1,2-diol, to pharmaceutical compositions comprising such crystalline polymorph forms, and to processes for preparing them. The invention further relates to methods of treatment of diabetes related disorders comprising administering such solid-state forms or compositions thereof to a subject, and to use of such crystalline polymorph forms in the manufacture of medicaments.
Abstract translation: 本发明涉及（1S）-1- [5 - （{3 - [（2-甲基吡啶-3-基）氧基] -5-（吡啶-2-基硫烷基）吡啶-2-基} 氨基）-1,2,4-噻二唑-3-基]乙烷-1,2-二醇，包括这种结晶多晶型物的药物组合物及其制备方法。 本发明还涉及治疗糖尿病相关病症的方法，包括将这种固态形式或其组合物施用于受试者，以及在制备药物中使用这种结晶多晶型物。
-
15.发明授权Intermediates for the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives 有权用于制备吡啶-2-基 - 氨基-1,2,4-噻二唑衍生物的中间体公开(公告)号：US09079890B2
公开(公告)日：2015-07-14
申请号：US14494430
申请日：2014-09-23
Applicant: Array BioPharma Inc.
Inventor： Thomas Daniel Aicher , Steven Armen Boyd , Mark Joseph Chicarelli , Kevin Ronald Condroski , Jay Bradford Fell , John P. Fischer , Indrani W. Gunawardana , Ronald Jay Hinklin , Ajay Singh , Timothy M. Turner , Eli M. Wallace
IPC: C07D417/00 , C07D401/14 , C07D417/14 , C07D213/75 , C07D417/12 , C07D401/12
CPC classification number: C07D401/14 , C07D213/75 , C07D401/12 , C07D417/12 , C07D417/14
Abstract: Provided are intermediates having the formulas wherein R2, R3, and L are as defined in the specification, which are useful in the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives.
Abstract translation: 提供具有下式的中间体其中R2，R3和L如说明书中所定义，其可用于制备吡啶-2-基 - 氨基-1,2,4-噻二唑衍生物。
-
Patent Agency Ranking
公开(公告)号：US08981085B2
公开(公告)日：2015-03-17
申请号：US14271129
申请日：2014-05-06
Applicant: Array BioPharma Inc.
Inventor： Yvan Le Huerou , James F. Blake , Indrani W. Gunawardana , Peter J. Mohr , Eli M. Wallace , Bin Wang , Mark Joseph Chicarelli , Michael Lyon
IPC: C07D471/04
CPC classification number: C07D471/04 , C07D401/06 , C07D519/00
Abstract: Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
Abstract translation: 式I的化合物可用于抑制CHK1和/或CHK2。 公开了使用式I化合物及其立体异构体及其药学上可接受的盐在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。
-
17.发明授权公开(公告)号：US10766881B2
公开(公告)日：2020-09-08
申请号：US16276326
申请日：2019-02-14
Applicant: Array BioPharma Inc.
Inventor： Steven W. Andrews , James F. Blake , Adam Cook , Indrani W. Gunawardana , Kevin W. Hunt , Andrew T. Metcalf , David Moreno , Li Ren , Tony P. Tang
IPC: C07D403/14 , C07D413/14 , C07D401/14 , G01N33/574 , A61K31/501 , A61K45/06 , A61K31/5377 , C12Q1/6886
Abstract: Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.
-
18.发明授权公开(公告)号：US10208024B2
公开(公告)日：2019-02-19
申请号：US15333148
申请日：2016-10-24
Applicant: Array BioPharma, Inc.
Inventor： Steven W. Andrews , James F. Blake , Adam Cook , Indrani W. Gunawardana , Kevin W. Hunt , Andrew T. Metcalf , David Moreno , Li Ren , Tony P. Tang
IPC: C07D403/14 , C07D401/14 , C07D413/14 , A61K31/501 , A61K31/5377 , C12Q1/68 , A61K45/06 , C12Q1/6886 , G01N33/574
Abstract: Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R1, R2, R3, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.
-
公开(公告)号：US20160303126A1
公开(公告)日：2016-10-20
申请号：US15197479
申请日：2016-06-29
Applicant: Array BioPharma Inc. , Genentech, Inc.
Inventor： James F. Blake , Adam Cook , Indrani W. Gunawardana , Kevin W. Hunt , Michael Lyon , Andrew T. Metcalf , Peter J. Mohr , David A. Moreno , Brad Newhouse , Li Ren , Tony P. Tang , Allen A. Thomas , Jacob Schwarz , Jane Schmidt , Lewis Gazzard , Huifen Chen
IPC: A61K31/506 , C07D403/14 , C07D471/04 , A61K31/4439 , C07D417/14 , C07D403/04 , C07D401/14 , A61K31/444 , A61K45/06 , C07D405/14
CPC classification number: A61K31/506 , A61K31/4439 , A61K31/444 , A61K45/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D417/14 , C07D471/04
Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
-
公开(公告)号：US09365568B2
公开(公告)日：2016-06-14
申请号：US14591691
申请日：2015-01-07
Applicant: Array BioPharma Inc.
Inventor： Yvan Le Huerou , James F. Blake , Indrani W. Gunawardana , Peter J. Mohr , Eli M. Wallace , Bin Wang , Mark Joseph Chicarelli , Michael Lyon
IPC: C07D495/14 , C07D471/04 , C07D401/06
CPC classification number: C07D471/04 , C07D401/06 , C07D519/00
Abstract: Compounds of Formula I are useful for inhibition of CHK1 and/or CHK2. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
-
-
-
-
-
-
-
-
-
Search Results
22
records
(took 0.036 seconds)
